Published in J Med Chem on July 11, 2012
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation. J Infect Dis (2013) 1.71
Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. PLoS One (2016) 1.39
Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening. J Biomol Screen (2014) 1.00
Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. J Med Chem (2014) 0.96
Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness. PLoS Negl Trop Dis (2014) 0.95
Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites. Antimicrob Agents Chemother (2015) 0.87
Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target. Antimicrob Agents Chemother (2013) 0.84
5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors. ACS Infect Dis (2016) 0.83
In silico discovery of aminoacyl-tRNA synthetase inhibitors. Int J Mol Sci (2014) 0.83
Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification. Org Biomol Chem (2014) 0.82
Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei. Eukaryot Cell (2014) 0.82
Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. Mol Biochem Parasitol (2013) 0.81
Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors. Eur J Med Chem (2016) 0.80
Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents. Bioorg Med Chem Lett (2013) 0.79
Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases. Antimicrob Agents Chemother (2015) 0.79
Emergence and evolution. Top Curr Chem (2014) 0.78
A binding hotspot in Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens. Acta Crystallogr D Biol Crystallogr (2015) 0.77
Comparison of histidine recognition in human and trypanosomatid histidyl-tRNA synthetases. Biochimie (2014) 0.76
Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Leishmania donovani tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts. Biochimie (2017) 0.75
Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors. Bioorg Med Chem (2016) 0.75
From cells, to mice, to target: Characterization of NEU-1053 (SB-443342) and its analogs for treatment of human African trypanosomiasis. ACS Infect Dis (2017) 0.75
Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis. J Med Chem (2016) 0.75
Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors. Bioorg Med Chem Lett (2017) 0.75
Development of methionyl-tRNA synthetase inhibitors as antibiotics for Gram-positive bacterial infections. Antimicrob Agents Chemother (2017) 0.75
Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol (1989) 7.06
Human African trypanosomiasis. Lancet (2009) 5.60
High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen (2001) 4.75
The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop (1997) 4.73
Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem (2004) 3.73
An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science (2007) 2.82
Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther (2001) 2.67
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther (2002) 2.21
From one amino acid to another: tRNA-dependent amino acid biosynthesis. Nucleic Acids Res (2008) 1.88
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm (2004) 1.56
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J Med Chem (2002) 1.42
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen (2009) 1.25
Characterization of the human mitochondrial methionyl-tRNA synthetase. Biochemistry (2004) 1.19
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res (2003) 1.14
Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol (2009) 1.12
Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. Bioorg Med Chem Lett (2004) 1.05
Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob Agents Chemother (2008) 1.01
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie (2010) 0.93
Aryl urea analogs with broad-spectrum antibacterial activity. Bioorg Med Chem Lett (2004) 0.89
Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 2.71
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
Type II secretion: from structure to function. FEMS Microbiol Lett (2006) 2.51
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Structure of the GspK-GspI-GspJ complex from the enterotoxigenic Escherichia coli type 2 secretion system. Nat Struct Mol Biol (2008) 2.19
The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A (2002) 2.10
The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol (2012) 1.96
Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure (2009) 1.89
Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem (2009) 1.87
Sites of interaction between aldolase and thrombospondin-related anonymous protein in plasmodium. Mol Biol Cell (2003) 1.83
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
The 1.6-A crystal structure of the class of chaperones represented by Escherichia coli Hsp31 reveals a putative catalytic triad. Proc Natl Acad Sci U S A (2003) 1.72
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation. J Infect Dis (2013) 1.71
High resolution crystal structure of a key editosome enzyme from Trypanosoma brucei: RNA editing ligase 1. J Mol Biol (2004) 1.67
Structural basis for the activation of cholera toxin by human ARF6-GTP. Science (2005) 1.66
Structural basis for UTP specificity of RNA editing TUTases from Trypanosoma brucei. EMBO J (2005) 1.61
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Secretins: dynamic channels for protein transport across membranes. Trends Biochem Sci (2011) 1.58
Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem (2012) 1.56
Crystal structure of the extracellular protein secretion NTPase EpsE of Vibrio cholerae. J Mol Biol (2003) 1.55
The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (2002) 1.51
An improved protocol for rapid freezing of protein samples for long-term storage. Acta Crystallogr D Biol Crystallogr (2003) 1.49
Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem Biol (2003) 1.47
Structure of the cholera toxin secretion channel in its closed state. Nat Struct Mol Biol (2010) 1.44
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol (2002) 1.37
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res (2005) 1.36
Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet (2003) 1.36
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. Genes Dev (2012) 1.33
The X-ray structure of the type II secretion system complex formed by the N-terminal domain of EpsE and the cytoplasmic domain of EpsL of Vibrio cholerae. J Mol Biol (2005) 1.33
The power of vanadate in crystallographic investigations of phosphoryl transfer enzymes. FEBS Lett (2004) 1.32
Aldolase provides an unusual binding site for thrombospondin-related anonymous protein in the invasion machinery of the malaria parasite. Proc Natl Acad Sci U S A (2007) 1.31
GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv (2002) 1.29
Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. J Struct Funct Genomics (2009) 1.28
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27
Structures of Mycobacterium tuberculosis DosR and DosR-DNA complex involved in gene activation during adaptation to hypoxic latency. J Mol Biol (2005) 1.26
Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen (2009) 1.25
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis (2013) 1.23
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol (2008) 1.22
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest (2012) 1.22
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
Synergistic stimulation of EpsE ATP hydrolysis by EpsL and acidic phospholipids. EMBO J (2006) 1.21
Crystal structures of the response regulator DosR from Mycobacterium tuberculosis suggest a helix rearrangement mechanism for phosphorylation activation. J Mol Biol (2008) 1.20
Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol (2008) 1.20
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure (2012) 1.18
Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem (2005) 1.18
The closed MTIP-myosin A-tail complex from the malaria parasite invasion machinery. J Mol Biol (2007) 1.15
The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol (2006) 1.14
The structure of the cytoplasmic domain of EpsL, an inner membrane component of the type II secretion system of Vibrio cholerae: an unusual member of the actin-like ATPase superfamily. J Mol Biol (2004) 1.14
Structural and functional studies of EpsC, a crucial component of the type 2 secretion system from Vibrio cholerae. J Mol Biol (2006) 1.13
Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase (MtbThyX) at 2.0A resolution. J Mol Biol (2005) 1.13
Structural and functional studies on the interaction of GspC and GspD in the type II secretion system. PLoS Pathog (2011) 1.12
Structure of the minor pseudopilin EpsH from the Type 2 secretion system of Vibrio cholerae. J Mol Biol (2007) 1.12
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett (2012) 1.12
The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol (2009) 1.11
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem (2010) 1.11